Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer

Annals of Surgical Oncology

Volumn 19, Issue 5, 2012, Pages 1508-1516

  Kaufmann, Manfred ^a   Von Minckwitz, Gunter ^b   Mamounas, Elefhterios P ^c   Cameron, David ^d   Carey, Lisa A ^e   Cristofanilli, Massimo ^f   Denkert, Carsten ^g   Eiermann, Wolfgang ^h   Gnant, Michael ⁱ   Harris, Jay R ^j   Karn, Thomas ^a   Liedtke, Cornelia ^k   Mauri, Davide ^l   Rouzier, Roman ^m   Ruckhaeberle, Eugen ^a   Semiglazov, Vladimir ⁿ   Symmans, W Fraser ^o   Tutt, Andrew ^p   Pusztai, Lajos ^o  

^a GOETHE UNIVERSITY   (Germany)

^b Department of Gynecology and Obstetrics Klinikum Offenbach   (Germany)

^c Aultman Cancer Center   (United States)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h University Women's Hospital   (Germany)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j HARVARD MEDICAL SCHOOL   (United States)

^k UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^l General Hospital of Lamia   (Greece)

^m HÔPITAL TENON   (France)

ⁿ N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^o UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^p GUY S HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BIOLOGICAL MARKER; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; VINCRISTINE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; CONSENSUS; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; INTERNATIONAL COOPERATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; POSTMENOPAUSE; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIMARY TUMOR; RECURRENCE FREE SURVIVAL; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BREAST NEOPLASMS; CHEMORADIOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORECASTING; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PRACTICE GUIDELINES AS TOPIC;

EID: 84862512775     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2108-2     Document Type: Article

References (71)

1. Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives, 2006. Ann Oncol. 2007;18:1927-34. (Pubitemid 350286227)
2. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940-9. (Pubitemid 46638994)
3. Caudle AS, Hunt KK. The neoadjuvant approach in breast cancer treatment: it is not just about chemotherapy anymore. Curr Opin Obstet Gynecol. 2011;23:31-6.
4. Von Minckwitz G, Kaufmann M, Kuemmel S, et al., for the GBG and AGO-B Study Groups. Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: results from the German neoadjuvant meta-analysis. J Clin Oncol. 2011;29(Suppl.):1028.
5. Montagna E, Bagnardi V, Rotmensz N, et al. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res Treat. 2010;124:689-99.
6. Kaufmann M, Pusztai L; Biedenkopf Expert Panel Members. Use of standard markers and incorporation of molecular markers into breast cancer therapy. Cancer. 2011;117:1575-82.
7. Robertson RM, Bondy M, Yang W, et al. Inflammatory breast cancer. CA Cancer J Clin. CA Cancer J Clin. 2010;60:351-75.
8. Boughey JC, Wagner J, Garrett BJ, et al. Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol. 2009;16:1606-11.
9. Boughey JC, Peintinger F, Meric-Bernstam F, et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006;244: 464-70.
10. Kim SI, Sohn J, Koo JS, Park SH, Park HS, Park BW. Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Oncology. 2010;79: 324-30.
11. Huober J, von Minckwitz G, Denkert C, et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat. 2010;124:133-40.
12. Penault-Llorca F, Abrial C, Raoelfils I, et al. Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. Hum Pathol. 2008;39:1221-8.
13. Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25:2650-5. (Pubitemid 47123169)
14. Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008;26:814-9. (Pubitemid 351265335)
15. Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002;95:681-95. (Pubitemid 34845919)
16. Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008; 100:1380-8.
17. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48-72
18. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-45. (Pubitemid 350003059)
19. Londero V, Bazzocchi M, Del Frate C, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol. 2004;14:1371-9. (Pubitemid 39162217)
20. Schott AF, Roubidoux MA, Helvie MA, et al. Clinical and radiological assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2005;92:231-8. (Pubitemid 41282819)
21. Roubidoux MA, LeCarpentier GL, Fowlkes JB, et al. Sonographic evaluation of early-stage breast cancers that undergo neoadjuvant chemotherapy. J Ultrasound Med. 2005;24:885-95. (Pubitemid 40885171)
22. Yang WT, Le-Petross HT, Macapinlac H, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat. 2008;109:417-26.
23. van Deurzen CH, Vriens BE, Tjan-Heijnen VC, et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer. 2009;45:3124-30.
24. Schwartz GF, Tannebaum JE, Jernigan AM, Palazzo JP. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast. Cancer. 2010;116:1243-51.
25. Budman DR. Dose and schedule as determinants of outcomes in chemotherapy for breast cancer. Semin Oncol. 2004;31(6 Suppl. 15):3-9. (Pubitemid 40075511)
26. Caudle AS, Gonzalez-Angulo AM, Hunt KK, et al. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28:1821-8.
27. Rouzier R, Pusztai L, Delaloge S, et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 2005;23:8331-9.
28. Lee JK, Coutant C, Kim YC, et al. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2010; 16:711-8.
29. Tabchy A, Valero V, Vidaurre T, et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. 2010;16:5351-61.
30. von Minckwitz G, Kaufmann M, Kümmel S, et al. Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane ± trastuzumab containing chemotherapy. Cancer Res. 2009;69(Suppl. 2):79.
31. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007;13:228-33. (Pubitemid 46121873)
32. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2- positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2- negative cohort. Lancet. 2010;375(9712):377-84.
33. Guarneri V, Frassoldati A, Bottini A, et al. Safety and activity report of a randomized phase II trial of preoperative anthracycline- based chemotherapy plus lapatinib, trastuzumab or both in HER2 positive breast cancer: CHERLOB Trial. Cancer Res. 2009;69(Suppl. 3):1093.
34. Rayson D, Suter T, van der Vegt S, et al. Interim results of BACH: randomized phase ii trial evaluating the safety of two chemotherapy regimens as adjuvant therapy in patients with HER2-positive breast cancer: PLD + cyclophosphamide + trastuzumab (PLD + C + H), or doxorubicin + cyclophosphomide (A + C), each followed by paclitaxel + trastuzumab (T + H). Cancer Res. 2009;69(24 Suppl. 3):2085.
35. Mathew J, Asgeirsson KS, Jackson LR, Cheung KL, Robertson JF. Neoadjuvant endocrine treatment in primary breast cancer - review of literature. Breast. 2009;18:339-44.
36. Smith IE, Dowsett M, Ebbs SR, et al.; IMPACT Trialists Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23:5108-16. (Pubitemid 46224019)
37. Eiermann W, Paepke S, Appfelstaedt J, et al.; Letrozole Neo- Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001;12:1527-32. (Pubitemid 34065880)
38. Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110:244-54. (Pubitemid 47121883)
39. Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer. 2006;106:2095-103. (Pubitemid 43673229)
40. Ellis MJ, Buzdar A, Unzeitig GW, et al. ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer (abstract LBA513). J Clin Oncol. 2010;28(Suppl.):18 s.
41. Fourquet A, Stoppa-Lyonnet D, Kirova YM, Sigal-Zafrani B, Asselain B; Institut Curie Breast Cancer Study Group; Institut Curie Breast Ovary Cancer Risk Study Group. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status. Am J Clin Oncol. 2009;32:127-31.
42. Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010;121:389-98.
43. Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28: 375-9.
44. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28:1145-53.
45. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123-34.
46. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;24;376(9737):235-44.
47. Loibl S, von Minckwitz G, Gwyn K, et al. Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer. 2006;106:237-46. (Pubitemid 43100430)
48. Gianni L, Pienkowski T, Im YH, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study ("NeoSphere"). Cancer Res. 2011; 70:S3-2.
49. Baselga J, Bradbury I, Eidtmann H, et al. First results of the NeoALTTO Trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2- positive primary breast cancer. Cancer Res. 2011;70:S3-3.
50. Kaufmann M, Morrow M, von Minckwitz G, Harris JR; Biedenkopf Expert Panel Members. Locoregional treatment of primary breast cancer: consensus recommendations from an international expert panel. Cancer. 2010;116:1184-91.
51. Houssami N, Macaskill P, Marinovich ML, et al. Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. Eur J Cancer. 2010;46:3219-32.
52. Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011;22:515-23.
53. Smith BD, Bentzen SM, Correa CR, et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;22:515-23.
54. Mamounas EP, Anderson SJ, Bear HD, et al. Predictors of locoregional failure (LRF) in patients receiving neoadjuvant chemotherapy (NC): results from combined analysis of NSABP B-18 and NSABP B-27 (abstract 90). Presented at the 2010 ASCO Breast Cancer Symposium.
55. Buchholz TA, Tucker SL, Masullo L, et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol. 2002;20:17-23. (Pubitemid 34032591)
56. Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist. 2010;15:1164-8.
57. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009; 360:679-91.
58. Coleman RE, Winter MC, Cameron D, et al.; AZURE (BIG01/ 04) Investigators. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer. 2010;102:1099-105.
59. Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010;11:421-8.
60. Debled M, Mauriac L. Neoadjuvant chemotherapy: are we barking up the right tree? Ann Oncol. 2010;21:675-9.
61. Hutcheon AW, Heys SD, Sarkar TK; Aberdeen Breast Group. Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat. 2003;79(Suppl. 1):S19-S24. (Pubitemid 36801907)
62. Untch M, Möbus V, Kuhn W, et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 2009;27:2938-45.
63. Frasci G, D'Aiuto G, Comella P, et al. Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908. Ann Oncol. 2010;21:707-16.
64. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2- positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2- negative cohort. Lancet. 2010;375:377-84.
65. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676-85.
66. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24:2019-27. (Pubitemid 46622110)
67. Evans TR, Yellowlees A, Foster E, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol. 2005;23:2988-95. (Pubitemid 46224118)
68. Buzdar AU, Singletary SE, Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999;17:3412-17. (Pubitemid 29517908)
69. Baldini E, Gardin G, Giannessi PG, et al. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann Oncol. 2003;14:227-32. (Pubitemid 36305434)
70. Smith IE, A'Hern RP, Coombes GA, et al. TOPIC Trial Group. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neoadjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol. 2004;15:751-58. (Pubitemid 38714736)
71. Chua S, Smith IE, A'Hern RP, et al. TOPIC Trial Group. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/ cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Ann Oncol. 2005;16:1435-41. (Pubitemid 41222415)